Physician profile
John A Vainder
NPI 1508858226
$5,629.52
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,484 · 2020: $761 · 2021: $781 · 2022: $963 · 2023: $1,347 · 2024: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,640.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,293.12 | 2019-2024 | Rinvoq, Skyrizi, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $993.88 | 2019-2024 | Entyvio, Gattex |
| Janssen Biotech, INC. | $699.32 | 2019-2024 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $356.43 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $349.87 | 2019-2023 | |
| Qol Medical, LLC | $321.54 | 2019-2024 | Sucraid |
| Braintree Laboratories, INC. | $284.60 | 2019-2023 | Sutab |
| Allergan, INC. | $185.33 | 2019-2020 | |
| Redhill Biopharma INC. | $152.46 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Celgene Corporation | $147.47 | 2022-2023 | Zeposia |
| Romark Laboratories, Lc | $119.91 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.71 | 2023-2024 | Cyltezo |
| Pfizer INC. | $92.23 | 2019-2023 | |
| Evoke Pharma, INC. | $70.36 | 2022-2023 | Gimoti |
| Janssen Scientific Affairs, LLC | $61.67 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $56.43 | 2023-2024 | Dupixent |
| Concordia Pharmaceuticals INC. | $46.94 | 2019 | |
| Daiichi Sankyo INC. | $46.28 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $45.36 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $43.93 | 2023 | Ocaliva |
| Genzyme Corporation | $30.76 | 2022 | |
| Merck Sharp & Dohme LLC | $30.39 | 2020-2022 | |
| Medtronic, INC. | $29.31 | 2021 | |
| Ferring Pharmaceuticals INC. | $24.55 | 2021 | |
| Shire North American Group INC | $20.01 | 2019 | |
| Ardelyx, INC. | $16.12 | 2024 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $15.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$52,803.89 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vainder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.